NUWE News & Events

Nuwellis announced that it has entered into a securities purchase agreement with an institutional and accredited investor for the purchase and sale of 994,537 shares of the company's common stock, together with warrants to purchase 1,989,074 shares of Common Stock in a private placement priced at-the-market under Nasdaq rules. The combined effective offering price for each Share and Private Placement Warrant is $3.09. The Private Placement Warrants will have an exercise price of $2.84 per share, will be exercisable immediately upon issuance, and will expire on the five-year anniversary of the date that a resale registration statement related to the Shares and Private Placement Warrants becomes effective. The company also announced that it has entered into a warrant inducement agreement with the Investor for the immediate exercise of certain outstanding warrants that the company issued on November 6, 2024 and June 10, 2025, in a transaction priced at-the-market under Nasdaq rules. Pursuant to the warrant inducement agreement, the Investor has agreed to a reduced exercise price of the outstanding Existing Warrants to an amended exercise price of $3.09, and to exercise the outstanding Existing Warrants to purchase an aggregate of 623,585 shares of the company's common stock. In consideration for the immediate exercise of the Existing Warrants, the company also agreed to issue the Investor unregistered warrants to purchase an aggregate of 1,247,170 shares of the Common Stock. The New Warrants will have an exercise price of $2.84 per share, will be exercisable immediately upon issuance, and will expire on the five-year anniversary of the date that a resale registration statement related to the New Warrants becomes effective. The gross proceeds from the Private Placement and the Warrant Inducement are expected to be approximately $5M, prior to deducting placement agent fees and estimated offering expenses. The Private Placement and the Warrant Inducement are expected to close on or about January 30, subject to the satisfaction of customary closing conditions. Ladenburg Thalmann & Co. acted as the sole placement agent for the Private Placement and the Warrant Inducement.

Nuwellis announced that it has entered into a Securities Purchase Agreement to acquire all of the issued and outstanding capital stock of Rendiatech Ltd., an Israeli-based medical technology company focused on automated kidney function monitoring. The transaction is expected to close following the satisfaction of customary closing conditions. The transaction has been approved by the boards of directors of both companies.

Nuwellis announced that the United States Patent and Trademark Office recently issued a new U.S. patent covering advanced safety mechanisms for blood return line clamps used in extracorporeal blood filtration systems. The issued patent corresponds to U.S. Patent Application No. 18/298,810 and is assigned to Nuwellis. The newly issued patent protects safety-focused design innovations intended to improve the reliability and consistency of blood flow control in extracorporeal circuits, with particular relevance for pediatric applications, where precision and safety are critical. These mechanisms are designed to support stable system performance and enhance protection in therapies involving small patient volumes and sensitive extracorporeal conditions.

Nuwellis announced the presentation of new real-world data from New York City's Lenox Hill Hospital at the 2025 American Society of Nephrology, ASN, Kidney Week, reinforcing the versatility of Aquadex ultrafiltration therapy in patients with acute kidney injury, AKI, and complex fluid management needs. The retrospective analysis, titled "Diversifying Aquapheresis Applications in Critical Care: Nephrology-Led Institutional Experience," reviewed 69 cases treated with Aquadex between 2018 and 2024. The study demonstrated effective and predictable fluid removal in patients with multiple underlying conditions-ranging from oliguric AKI and post-cardiac-surgery volume overload to pre-operative optimization in end-stage renal disease. The analysis found that patients had an average of 6.4 liters of ultrafiltrate removed over a mean duration of 78 hours, with stable hemodynamics even among those on vasopressor support.